RxDoctor Payments DataLook up a doctor →

Elena Anisimova, MD

Internal Medicine · Denver, CONPI 1770564437

Payments from drug & device makers

$36,320in general payments, 2019–2025

Across 1,539 payments — averaging $23.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$7K
  • AstraZeneca$4K
  • AbbVie$4K
  • Amgen$2K
  • Johnson & Johnson$2K
  • Novo Nordisk$1K
  • plus $16K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Smith+Nephew40$6,966
AstraZeneca(2 entities)163$4,129
AbbVie(2 entities)206$4,069
Amgen(2 entities)121$2,244
Johnson & Johnson(2 entities)77$1,637
Novo Nordisk78$1,372
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC96$1,288
Novartis72$1,175
Lilly USA, LLC66$955
Antares Pharma, Inc.46$948
Boehringer Ingelheim36$822
Bayer38$800
Astellas Pharma US Inc22$767
Pfizer34$658
Esperion Therapeutics, Inc.23$503
GSK21$497
Organogenesis Inc.14$467
Ardelyx, Inc.23$423
Sumitomo Pharma America, Inc.16$369
Madrigal Pharmaceuticals13$335
Merck21$325
Radius Health, Inc.16$317
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)21$312
Nestle Healthcare Nutrition Inc.19$291
Otsuka America Pharmaceutical, Inc.13$286
Amarin Pharma, Inc.15$277
Exact Sciences13$264
ANI Pharmaceuticals, Inc.18$259
Lundbeck LLC10$245
Sunovion Pharmaceuticals Inc.13$243
Aimmune Therapeutics, Inc.14$205
Scilex Pharmaceuticals Inc.10$187
Mannkind Corporation10$185
Biowound Solutions, Inc.6$174
Takeda Pharmaceuticals U.S.A., Inc.10$174
Biohaven Pharmaceutical Holding Company Ltd.8$171
Eisai Inc.12$171
Biohaven Pharmaceuticals, Inc.9$165
Electromed, Inc.15$145
Regeneron Healthcare Solutions, Inc.9$143
Idorsia Pharmaceuticals US Inc7$136
Kowa Pharmaceuticals America, Inc.7$124
Clarus Therapeutics Inc.6$101
Phathom Pharmaceuticals, Inc.4$77
Axsome Therapeutics, Inc.3$77
Heartflow, Inc.3$67
Ironwood Pharmaceuticals, Inc3$66
Redhill Biopharma Inc.4$64
Halozyme Inc3$64
E.r. Squibb & Sons, L.L.C.3$61
Insmed, Inc.3$55
Paratek Pharmaceuticals, Inc.3$50
Azurity Pharmaceuticals, Inc.2$47
IBSA Pharma Inc.2$46
Vertex2$44
MDD US Operations, LLC2$36
Genentech USA, Inc.2$35
USWM, LLC2$31
Mylan Specialty L.p.1$30
Abbott1$27

How this compares

$36,320 in reported general payments places this provider in the 95th percentile of 1,430 internal medicine providers in Colorado.

See all internal medicine providers in Colorado →

Medicare billing

Part B allowed, 2024
$2,872,167
Medicare patients
384
Services billed
13,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Denver

See the full list for Colorado →

Where these figures come from

Is this you, or does something look wrong? →